Other languages Johnson & Johnson Borsa Italiana

Equities

4JNJ

US4781601046

End-of-day quote Borsa Italiana Other stock markets 23:00:00 30/05/2024 BST			5-day change	1st Jan Change
135.3 ^EUR	+1.23%		-1.15%	-3.78%

05-31	Sector Update: Health Care Stocks Higher Late Afternoon	MT
05-31	US lawmakers ask FBI for briefing on GenScript Biotech's links to China	RE

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Sector Update: Health Care Stocks Higher Late Afternoon	05-31
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	05-31
Sector Update: Health Care Stocks Advance Friday Afternoon	05-31
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	05-31
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	05-31
J&J : finalise l'acquisition de Shockwave Medical	05-31
Johnson & Johnson Closes Acquisition of Shockwave Medical	05-31
Johnson & Johnson Completes Acquisition of Shockwave Medical	05-31
Johnson & Johnson Completes Acquisition of Shockwave Medical	05-31
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers.	05-30
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	05-30
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	05-29
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM	05-29
J&J : résultats encourageants dans le soin de la dépression	05-29
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	05-29
J&J's treatment for depression succeeds in late stage study	05-29
Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes	05-29
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	05-29
Sector Update: Health Care Stocks Fall Late Afternoon	05-28
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	05-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm